Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Legend Biotech Corp ADR (LEGN)

Legend Biotech Corp ADR (LEGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,224,167
  • Shares Outstanding, K 182,634
  • Annual Sales, $ 285,140 K
  • Annual Income, $ -518,250 K
  • EBIT $ -170 M
  • EBITDA $ -149 M
  • 60-Month Beta 0.08
  • Price/Sales 21.79
  • Price/Cash Flow N/A
  • Price/Book 5.56

Options Overview Details

View History
  • Implied Volatility 74.90% ( -8.65%)
  • Historical Volatility 49.65%
  • IV Percentile 94%
  • IV Rank 57.72%
  • IV High 105.05% on 07/12/24
  • IV Low 33.74% on 12/21/23
  • Put/Call Vol Ratio 21.40
  • Today's Volume 336
  • Volume Avg (30-Day) 319
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 15,526
  • Open Int (30-Day) 12,903

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.31
  • Number of Estimates 9
  • High Estimate -0.13
  • Low Estimate -0.60
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +22.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.50 +4.86%
on 12/19/24
44.56 -23.52%
on 12/04/24
-6.06 (-15.10%)
since 11/20/24
3-Month
32.50 +4.86%
on 12/19/24
51.77 -34.17%
on 10/15/24
-14.45 (-29.78%)
since 09/20/24
52-Week
32.50 +4.86%
on 12/19/24
70.13 -51.40%
on 02/27/24
-25.93 (-43.21%)
since 12/20/23

Most Recent Stories

More News
Legend Biotech CEO to Present Company Updates at 43rd Annual J.P. Morgan Healthcare Conference

Legend Biotech's CEO will present company updates at the J.P. Morgan Healthcare Conference on January 14, 2025.Quiver AI SummaryLegend Biotech Corporation announced that CEO Ying Huang, Ph.D., will present...

LEGN : 34.08 (+0.18%)
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

LEGN : 34.08 (+0.18%)
Legend Biotech Reports 89% MRD Negativity in CARTITUDE-4 Study for CARVYKTI® in Multiple Myeloma After Three-Year Follow-Up

New data shows CARVYKTI® achieves 89% MRD negativity in multiple myeloma patients, significantly surpassing standard therapies.Quiver AI SummaryLegend Biotech has announced promising results from its...

LEGN : 34.08 (+0.18%)
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

LEGN : 34.08 (+0.18%)
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

LEGN : 34.08 (+0.18%)
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

LEGN : 34.08 (+0.18%)
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

LEGN : 34.08 (+0.18%)
Legend Biotech Appoints Alan Bash as President of CARVYKTI®

LEGN : 34.08 (+0.18%)
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

LEGN : 34.08 (+0.18%)
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

LEGN : 34.08 (+0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in...

See More

Key Turning Points

3rd Resistance Point 35.86
2nd Resistance Point 35.38
1st Resistance Point 34.73
Last Price 34.08
1st Support Level 33.59
2nd Support Level 33.11
3rd Support Level 32.46

See More

52-Week High 70.13
Fibonacci 61.8% 55.76
Fibonacci 50% 51.31
Fibonacci 38.2% 46.87
Last Price 34.08
52-Week Low 32.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar